Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
- Autores
- Paton, D. J.; Reeve, R.; Capozzo, Alejandra Victoria; Ludi, A.
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.
Instituto de Virología
Fil: Paton, D. J. The Pirbright Institute; Reino Unido
Fil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino Unido
Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ludi, A. The Pirbright Institute; Reino Unido - Fuente
- Vaccine 37 (37) : 5515-5524. (3 September 2019)
- Materia
-
Aphthovirus
Virus Fiebre Aftosa
Foot and Mouth Disease
Fiebre Aftosa
Vacuna
Serología
Control de Calidad
Protección
Vaccines
Serology
Quality Controls
Protection - Nivel de accesibilidad
- acceso restringido
- Condiciones de uso
- Repositorio
- Institución
- Instituto Nacional de Tecnología Agropecuaria
- OAI Identificador
- oai:localhost:20.500.12123/6312
Ver los metadatos del registro completo
id |
INTADig_2315911a58e1fbd53ad712fdc436de34 |
---|---|
oai_identifier_str |
oai:localhost:20.500.12123/6312 |
network_acronym_str |
INTADig |
repository_id_str |
l |
network_name_str |
INTA Digital (INTA) |
spelling |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratoryPaton, D. J.Reeve, R.Capozzo, Alejandra VictoriaLudi, A.AphthovirusVirus Fiebre AftosaFoot and Mouth DiseaseFiebre AftosaVacunaSerologíaControl de CalidadProtecciónVaccinesSerologyQuality ControlsProtectionFoot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.Instituto de VirologíaFil: Paton, D. J. The Pirbright Institute; Reino UnidoFil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino UnidoFil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ludi, A. The Pirbright Institute; Reino UnidoElsevier2019-11-07T17:43:18Z2019-11-07T17:43:18Z2019-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://www.sciencedirect.com/science/article/pii/S0264410X19310230http://hdl.handle.net/20.500.12123/63120264-410Xhttps://doi.org/10.1016/j.vaccine.2019.07.102Vaccine 37 (37) : 5515-5524. (3 September 2019)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccess2025-09-29T13:44:49Zoai:localhost:20.500.12123/6312instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:44:49.908INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse |
dc.title.none.fl_str_mv |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
title |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
spellingShingle |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory Paton, D. J. Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection |
title_short |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
title_full |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
title_fullStr |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
title_full_unstemmed |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
title_sort |
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory |
dc.creator.none.fl_str_mv |
Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. |
author |
Paton, D. J. |
author_facet |
Paton, D. J. Reeve, R. Capozzo, Alejandra Victoria Ludi, A. |
author_role |
author |
author2 |
Reeve, R. Capozzo, Alejandra Victoria Ludi, A. |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection |
topic |
Aphthovirus Virus Fiebre Aftosa Foot and Mouth Disease Fiebre Aftosa Vacuna Serología Control de Calidad Protección Vaccines Serology Quality Controls Protection |
dc.description.none.fl_txt_mv |
Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements. Instituto de Virología Fil: Paton, D. J. The Pirbright Institute; Reino Unido Fil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino Unido Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ludi, A. The Pirbright Institute; Reino Unido |
description |
Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-11-07T17:43:18Z 2019-11-07T17:43:18Z 2019-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0264410X19310230 http://hdl.handle.net/20.500.12123/6312 0264-410X https://doi.org/10.1016/j.vaccine.2019.07.102 |
url |
https://www.sciencedirect.com/science/article/pii/S0264410X19310230 http://hdl.handle.net/20.500.12123/6312 https://doi.org/10.1016/j.vaccine.2019.07.102 |
identifier_str_mv |
0264-410X |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/restrictedAccess |
eu_rights_str_mv |
restrictedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
Vaccine 37 (37) : 5515-5524. (3 September 2019) reponame:INTA Digital (INTA) instname:Instituto Nacional de Tecnología Agropecuaria |
reponame_str |
INTA Digital (INTA) |
collection |
INTA Digital (INTA) |
instname_str |
Instituto Nacional de Tecnología Agropecuaria |
repository.name.fl_str_mv |
INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria |
repository.mail.fl_str_mv |
tripaldi.nicolas@inta.gob.ar |
_version_ |
1844619139653566464 |
score |
12.559606 |